View Post

First-Line Palbociclib/Letrozole Shows Real-World Survival Benefit in HR+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting. Palbociclib (Ibrance) in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor (HR)–positive, HER2-negative, metastatic …

View Post

Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com Data from the pivotal phase 3 KATHERINE (NCT01772472) has led to the addition of ado-trastuzumab emtansine (T-DM1; Kadcyla) to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it, according to Jane L. Meisel, MD. The phase 3 KATHERINE trial …

View Post

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

In Clinical Studies News by Barbara Jacoby

Source: Newsfile Corp. From: finance.yahoo.com – The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment – Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and …

View Post

Surgery Boosts Survival in De Novo Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Locoregional treatment was found to improve survival for patients with de novo stage IV breast cancer and bone-only metastasis, according to the results of a multicenter registry study reported at the 17th St. Gallen International Breast Cancer Conference 2021. BOMET MF14-01 (ClinicalTrials.gov Identifier: NCT02125630) included 505 patients with de novo stage IV breast cancer …

View Post

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …

View Post

Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …

View Post

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

In Clinical Studies News by Barbara Jacoby

From: businesswire.com – Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA® and Puma’s NERLYNX® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test – This is Celcuity’s second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies – Five clinical trial collaborations …

View Post

BDC-1001 +/- Immune Checkpoint Inhibitor Therapy Under Investigation for HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com Currently, the only immune-based therapy for patients with HER2-driven or expressing cancers are anti-HER2 monoclonal antibodies. More treatment options are needed for patients who develop progressive disease. A trail in progress presented at the virtual 2020 San Antonio Breast Cancer Symposium suggests that immunostimulatory adjuvants such as toll-like receptor (TLR) 7/8 can help cause T-cells …

View Post

CONTESSA Trial Yields Positive Results for Patients with HER2-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA study of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer. New data suggests that a …